Cue Biopharma (CUE) Scheduled to Post Earnings on Monday

Cue Biopharma (NASDAQ:CUE) is set to announce its earnings results after the market closes on Monday, August 19th. Analysts expect the company to announce earnings of ($0.29) per share for the quarter.

Cue Biopharma Stock Performance

CUE opened at $0.63 on Wednesday. The firm’s fifty day simple moving average is $1.03 and its two-hundred day simple moving average is $1.62. Cue Biopharma has a 52-week low of $0.62 and a 52-week high of $3.25. The company has a market cap of $30.84 million, a price-to-earnings ratio of -0.60 and a beta of 1.96. The company has a quick ratio of 2.47, a current ratio of 2.47 and a debt-to-equity ratio of 0.11.

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. JMP Securities reduced their price target on shares of Cue Biopharma from $15.00 to $2.00 and set a “market outperform” rating for the company in a research report on Friday, July 26th. Piper Sandler cut their price objective on Cue Biopharma from $8.00 to $3.00 and set an “overweight” rating for the company in a research note on Friday, July 26th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Cue Biopharma has a consensus rating of “Buy” and an average price target of $5.80.

About Cue Biopharma

Cue Biopharma, Inc, a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer.